Certara Products Archives

Case Study

PBPK Assists with DDI Prediction Without a Rifampin Study for Cobimetinib

Cobimetinib (Cotellic®), approved by the US FDA in 2015, is a kinase inhibitor for treating…

Jim Gallagher2021 年 8 月 12 日

Blog

价值沟通制胜之道：导言

Drawn from the experiences of the BaseCase Consulting Team, this is the introduction to ‘Succeeding…

Certara2021 年 8 月 5 日

Case Study

使用 Simcyp Simulator 的 DDI 监管典范案例：Ibrutinib (Imbruvica®)

Pharmacylics and J&J sought to bring ibrutinib, its new tyrosine kinase inhibitor therapy targeting rare…

Jim Gallagher2021 年 7 月 29 日

视频

What is BaseCase?

Developing interactive and easy-to-use stakeholder engagement content market access, medical affairs, and sales field teams…

Certara2021 年 7 月 20 日

Case Study

治疗镰状细胞病的 Voxelotor：无需任何临床研究，利用剂量预测模型进行 DDI 预测

In November 2019, the US FDA granted accelerated approval for Oxbryta™ (voxelotor) tablets for the…

Jim Gallagher2021 年 7 月 14 日

Blog

Preparing for High Stakes Meetings; How to Best Convey a New Drug’s Value to Payers

This blog post includes key takeaways from the opening session of Certara’s first Strategic Evidence…

Certara2021 年 6 月 18 日

On-Demand Webinar

Three Pathways have emerged in Innovative Access Agreements

The days of simply determining the market demand for a new drug as a function…

Jim Gallagher2021 年 6 月 11 日

On-Demand Webinar

Outcomes Based Agreements

The days of simply determining the market demand for a new drug as a function…

Jim Gallagher2021 年 6 月 11 日

On-Demand Webinar

Stakeholder perspectives: current and potential benefits

Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…

Jim Gallagher2021 年 5 月 26 日

On-Demand Webinar

通过案例研究了解欧洲 HTA 和市场准入的优势和机遇

Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…

Jim Gallagher2021 年 5 月 26 日

Certara 产品

PBPK Assists with DDI Prediction Without a Rifampin Study for Cobimetinib

价值沟通制胜之道：导言

使用 Simcyp Simulator 的 DDI 监管典范案例：Ibrutinib (Imbruvica®)

What is BaseCase?

治疗镰状细胞病的 Voxelotor：无需任何临床研究，利用剂量预测模型进行 DDI 预测

Preparing for High Stakes Meetings; How to Best Convey a New Drug’s Value to Payers

Three Pathways have emerged in Innovative Access Agreements

Outcomes Based Agreements

Stakeholder perspectives: current and potential benefits

通过案例研究了解欧洲 HTA 和市场准入的优势和机遇

订阅时事通讯

快捷链接

解决方案

联系我们